Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Net Income (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Net Income for 15 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 46.37% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.7 million through Dec 2025, down 7.73% year-over-year, with the annual reading at -$15.7 million for FY2025, 7.73% down from the prior year.
  • Net Income for Q4 2025 was -$5.7 million at Plus Therapeutics, down from -$4.4 million in the prior quarter.
  • The five-year high for Net Income was -$1.5 million in Q2 2023, with the low at -$5.7 million in Q4 2025.
  • Average Net Income over 5 years is -$3.8 million, with a median of -$3.8 million recorded in 2023.
  • The sharpest move saw Net Income skyrocketed 72.04% in 2023, then tumbled 146.76% in 2024.
  • Over 5 years, Net Income stood at -$3.7 million in 2021, then plummeted by 50.56% to -$5.6 million in 2022, then soared by 32.09% to -$3.8 million in 2023, then decreased by 2.44% to -$3.9 million in 2024, then crashed by 46.37% to -$5.7 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$5.7 million, -$4.4 million, and -$1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.